The Trump administration is moving to end a federal subsidy program that helps lower insurers’ costs for Medicare prescription drug plans. Under the plan described by multiple outlets, the subsidies would end at the close of the current year, meaning their effect would disappear for coverage decisions and pricing that take effect in 2027. As a result, Medicare beneficiaries enrolled in drug plans could see higher out-of-pocket costs, including potential increases in monthly premiums. The subsidy program currently reduces financial pressure on insurers offering Medicare drug coverage, which in turn helps keep beneficiary costs lower than they otherwise would be. Both outlets characterize the policy change as potentially raising costs for millions of people who rely on Medicare drug plans, particularly older adults. The coverage implications depend on how insurers adjust premiums and benefits after the subsidy ends, but the reporting consistently indicates that the loss of the subsidy is expected to translate into higher consumer costs starting next year.